Finally, we validated the co-expression profile of FMO2 and SFRP1 in 8246 patients with breast cancer with DNA microarrays data (Figure 6E) and 4421 patients with breast cancer with RNA-sequence data (Figure 6F) from bc-GenExMiner and 1284 patients with breast cancer with TCGA breast cancer data from UCSC Xena (Figure 6G). The gene discussed is FMO2; the disease is breast carcinoma.